KRN5500
Phase 2- Indications
- Cancer-related neuropathic pain
Company intelligence / Profile preview
DARA BioSciences
Raleigh, North Carolina, United Statesdrug-dev.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Phase 2
01
Overview
DARA's lead clinical asset was KRN5500 for neuropathic pain in cancer patients, which completed a Phase 2a study and received Fast Track designation from the FDA. The company also launched several oncology support products including Soltamox® (oral tamoxifen), Bionect®, and Gelclair®, all focused on improving quality of life for oncology patients through symptom management and supportive care.
- Therapeutic areas
- GastroenterologyOncologyDermatologyNeurology
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Helsinn Group of Switzerland – exclusive U.S. commercial rights to GelclairKirin Pharmaceuticals – licensing agreement for drug candidates including KRN5500/Kirin compoundsBayer Pharmaceuticals Corporation – licensing partner
Beyond the preview
Go deeper on DARA BioSciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DARA BioSciences.